Koleva-Georgieva DN. Pharmacologic vitreolysis: New strategy for treatment of anomalous vitreo-macular adhesion. World J Ophthalmol 2015; 5(3): 99-105 [DOI: 10.5318/wjo.v5.i3.99]
Corresponding Author of This Article
Desislava N Koleva-Georgieva, MD, PhD, FEBO, Assistant Professor, Department of Ophthalmology, Faculty of Medicine, Medical University of Plovdiv, Pestersko shose 66, 4001 Plovdiv, Bulgaria. dr_desikoleva@yahoo.com
Research Domain of This Article
Ophthalmology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Ophthalmol. Aug 12, 2015; 5(3): 99-105 Published online Aug 12, 2015. doi: 10.5318/wjo.v5.i3.99
Pharmacologic vitreolysis: New strategy for treatment of anomalous vitreo-macular adhesion
Desislava N Koleva-Georgieva
Desislava N Koleva-Georgieva, Clinic of Ophthalmology, “St. George” Hospital, 4001 Plovdiv, Bulgaria
Desislava N Koleva-Georgieva, Department of Ophthalmology, Faculty of Medicine, Medical University of Plovdiv, 4001 Plovdiv, Bulgaria
Author contributions: Koleva-Georgieva DN solely contributed to this paper.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Desislava N Koleva-Georgieva, MD, PhD, FEBO, Assistant Professor, Department of Ophthalmology, Faculty of Medicine, Medical University of Plovdiv, Pestersko shose 66, 4001 Plovdiv, Bulgaria. dr_desikoleva@yahoo.com
Telephone: +359-32-602780 Fax: +359-32-602481
Received: January 29, 2015 Peer-review started: January 29, 2015 First decision: March 6, 2015 Revised: April 30, 2015 Accepted: July 16, 2015 Article in press: July 17, 2015 Published online: August 12, 2015 Processing time: 200 Days and 5.2 Hours
Core Tip
Core tip: Persistent anomalous vitreo-macular adhesion (VMA) is a well-known factor, associated with a variety of sight threatening diseases (macular hole, vitreo-macular traction syndrome, macular edema, exudative age-related macular degeneration). The release of traction has been of exclusive surgical capability. Notwithstanding good results, vitrectomy is hampered by the inability of complete vitreo-retinal separation and surgical complications. With aim to overcome limitations of surgery, investigators have made enormous progress with the advent of pharmacologic vitreolysis - a method for releasing VMA by intravitreal drug delivery. This paper aims to summarize the current knowledge and status of investigation on this new treatment approach.
